3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial

Key Points

• Romosozumab effectively increases bone mineral density in postmenopausal women with osteoporosis after both 3 and 12 months of treatment.
• The primary outcome measure includes a non-inferiority analysis based on bone mineral density changes at 12 months.
• Randomised controlled trial format allowed for direct comparison of treatment durations for effectiveness and safety.
• This study highlights the potential for shorter treatment durations, indicating better patient compliance possibly.